Overview

Current medications used for obesity management are highly limited in terms of efficacy and safety. There is a need to develop new, more effective, and reliable drugs or treatments. Studies and analyses of the underlying mechanisms of obesity pathophysiology have identified several promising drug targets and new therapeutic strategies to address obesity and its complications. Based on our deep understanding of obesity and extensive hands-on experience in anti-obesity research, Protheragen offers a development service for anti-obesity therapies targeting various receptors. We aim to help our clients make key decisions in the development of safer and more effective treatments or drugs through a variety of research support.

High-end Customised Anti-Obesity Therapy Development Service That Fully Meet Your Needs

Anti-obesity strategies exert their effects primarily by increasing energy expenditure, reducing energy intake, increasing energy excretion, or a combination of them. As a reliable partner in anti-obesity research, we offer a full range of services to support any scientific research needs. Specific services offered include the following:

• Target Screening

  Melanocortin 4 Receptor (MC4R)

  MC4R plays a crucial role in energy homeostasis. MC4R gene defects and impaired energy regulation are associated with obesity and metabolic disorders. We design and search for MC4R agonists or develop gene therapies targeting MC4R and test their potential and safety in treating obesity.

  Peroxisome Proliferator-Activated Receptors (PPARs)

  PPAR is a ligand-dependent transcription factor that contributes to the regulation of inflammation, lipid concentrations in the body, diabetes, etc. PPAR modulators have been developed for the treatment of obesity and obesity-related metabolic disorders. We develop efficient anti-obesity drugs or other therapeutic strategies targeting PPARs to help advance related research.

  Serotonin (5-HT) Receptors

  As a neurotransmitter, 5-HT has multiple functions in regulating mood and eating behavior. Inhibition of 5-HT synthesis has been found to reduce weight gain and ameliorate metabolic dysfunction in obese mouse models. We provide a personalized anti-obesity therapeutic development service for 5-HT, a novel target for the treatment of obesity.

  Cannabinoid Receptors (CB1 and CB2)

  The CB receptor is a novel pharmacological target for the study of anti-obesity therapies. CB2 agonists are found to induce anti-obesity effects and reduce food intake in mice. We provide an innovative anti-obesity therapeutic development service targeting CB1 and CB2.

  Orexin Receptors (OX-1 and OX-2)

  OX and its receptors are involved in the regulation of many functions of the central nervous system, including food consumption, energy homeostasis, and stress. OX deficiency leads to insulin sensitivity, glucose homeostasis, etc., and is associated with an increased risk of obesity. We develop anti-obesity therapies targeting OX receptors and assess their efficacy and safety through obesity models.

  Glucagon Receptor (GCGR)

  GCGR activation may be a novel therapeutic strategy to suppress obesity. We design and develop tailored and comprehensive experimental protocols for anti-obesity therapies targeting GCGR and complete relevant preclinical studies.

  Gastric Inhibitory Polypeptide (GIP) Receptor

  GIP is a duodenal hormone whose secretion is mainly caused by the absorption of ingested fat. We develop GIP receptor-modulating drugs and analyze the molecular mechanisms by which they lead to weight loss and reverse obesity.

  Sodium-Glucose Cotransporter

  Studies have identified the potential of sodium-glucose cotransporter inhibitors in the treatment of obesity and diabetes. We customize tailor-made solutions and research processes based on our client's actual research needs to accelerate obesity therapeutic research targeting sodium-glucose cotransporters.

• Anti-Obesity Therapy Development

  Based on in-depth studies of the pathogenesis of obesity and various receptors, we search for various potential therapeutic targets, develop related therapies, and design anti-obesity drugs.

  Gene Therapy Development

  We use various gene editing strategies (non-viral transfection, viral transfection, and precision genome editing) to introduce and regulate the expression of various genes and evaluate their effects on obesity models.

  Anti-obesity Drug Development

  We develop a variety of receptor antagonists, agonists, inhibitors, etc., which act to reduce body weight and improve metabolism and energy regulation by modulating targets in a wide range of systems and tissues.

  Cell Therapy Development

  Relying on cutting-edge technologies, we offer a comprehensive suite of anti-obesity cell therapy development services (stem cell therapy, CAR-T cell therapy, and others), ranging from therapy design and preclinical evaluation to detailed data analysis.

  Antibody Therapy Development

  We provide an anti-obesity antibody therapeutic development service based on phage display technology, hybridoma technology, and others covering high-throughput screening, optimization, and preclinical evaluation of anti-obesity antibodies.

  Tissue Engineering Therapy Development

  We focus on therapy design related to energy metabolism, adipose tissue function, etc., preclinical evaluation, and provide a cutting-edge tissue engineering therapy development service.

  Nanotherapy Development

  We also provide a cutting-edge anti-obesity nanotherapeutic development service for white adipose tissue, brown adipose tissue, and other targets with low side effects and superior efficacy.

• Preclinical Studies of Anti-Obesity Therapies

  Based on our state-of-the-art obesity model development platform, we carefully combine in vitro and in vivo studies to support preclinical research services for anti-obesity therapies targeting a variety of receptors, including pharmacokinetic studies, drug safety evaluations, and more.

  • Construction of Obesity Models
    We build animal models for in-depth studies of the therapeutic efficacy and safety of various potential anti-obesity drugs and therapies. Animal models that are constructed include the following:
    • Diet-induced animal model: This model is an ideal model to study obesity resistance due to its ability to respond well to the pathogenesis of obesity.
    • Gene Editing Models: Our scientists use cutting-edge gene editing technology to construct various gene mutation models to study the efficacy of different drugs or therapies.
    • Other models: In addition to this, we have other types of animal models for preclinical studies of anti-obesity therapies.
  • Evaluation of anti-obesity therapies
    We evaluate pharmacodynamics, pharmacokinetics, bioanalysis, and safety assessment to accelerate the study of anti-obesity therapies targeting various receptors.

    Pharmacodynamic Study

    • Food/Water Intake Assessment
    • Quantitative Analysis of Body Fat Distribution
    • Energy Expenditure Monitoring
    • Measurement of Ectopic Fat Accumulation
    • Molecular Biomarker Analysis

    Pharmacokinetic Study

    • DMPK Study of Anti-Obesity Drugs
    • ADME Study of Anti-Obesity Drugs

    Bioanalysis

    • Biological Analysis of Macromolecular Drugs
    • Bioanalysis of Small Molecule Drugs

    Safety Assessment

    • Safety Pharmacology Studies
    • Toxicology Studies

Workflow

Regardless of where you are in the development of anti-obesity therapies and preclinical studies, we provide the appropriate research services and develop tailored experimental strategies.

Applications

• The development of anti-obesity therapies targeting specific receptors helps advance research for more effective and targeted treatments that address inter-individual differences.
• Anti-obesity therapies targeting specific receptors help facilitate research into the treatment of obesity complications, such as cardiovascular disease and diabetes.
• The development of multi-targeted anti-obesity therapies plays an important role in the study of more efficient combination therapies.

Advantages

• We have a deep understanding of the uniqueness of each project and provide customized receptor-targeted anti-obesity therapy development services.
• Our experienced researchers provide our clients with receptor-targeted anti-obesity therapy study design, data interpretation, and other timely research assistance.
• Our state-of-the-art research facilities and rigorous experimental standards ensure that the data from anti-obesity therapy studies meet the high standards of the research field.

Comprehensive Services and Customized Solutions for Obesity Research

Protheragen is the foundation for the development of anti-obesity therapies by analyzing the causes of obesity from genetic, pharmacological, and disease perspectives. We also provide personalized obesity diagnosis and prediction services using a variety of cutting-edge genetic, metabolic, protein, and lipidomic technologies. Our tests cover a wide range of genes, biomarkers, and microbiome studies. At the same time, we use a variety of technologies to enable precision editing of obesity-related genes and to fuel obesity and therapy research. Given our extensive experimental experience in obesity research, we predict obesity risk, optimize diet and exercise programs, and help individuals achieve healthy weight management through hormone studies and diet analysis.

Publication Data

Frequently Asked Questions

What are the complications of obesity?

Obesity is associated with several complications that have a huge impact on life such as cardiovascular disease, non-alcoholic steatohepatitis, diabetes mellitus, chronic kidney disease, and various types of cancer.

What is the mechanism of action of anti-obesity drugs?

Anti-obesity drugs regulate various receptors to suppress appetite, reduce energy intake, increase energy expenditure, etc., to reduce body weight, regulate energy and metabolism, and other purposes.

Protheragen offers a personalized anti-obesity therapeutic development service targeting various receptors, including anti-obesity drugs and other potential therapeutic strategies. We stay at the forefront of anti-obesity research and the development of novel therapeutic approaches towards the development of multimodal and personalized obesity treatments. Please feel free to contact us for more information or to discuss specific experimental procedures.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Targeting Enzymes and Proteins for Developing Anti-Obesity Therapeutics
• Targeting Hormones and Peptides for Developing Anti-Obesity Therapeutics
• Targeting Metabolic Regulators for Developing Anti-Obesity Therapeutics
• Targeting Signaling Molecules for Developing Anti-Obesity Therapeutics